my-server
← Wiki

List of investigational chronobiotics

This is a list of investigational chronobiotics, or drugs that are currently under development for clinical use as chronobiotics—that is, for the treatment of circadian rhythm sleep disorders—but are not yet approved.

Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action [Reference]".

This list was last comprehensively updated in September 2025. It is likely to become outdated with time.

Under development

Phase 3

  • Solriamfetol (ADX-N05; ARL-N05; JZP-110; SKL-N05; Sunosi) – norepinephrine–dopamine reuptake inhibitor (NDRI) and trace amine-associated receptor 1 (TAAR1) agonist

Phase 2

  • Lemborexant (LEM; Dayvigo; E-2006) – orexin OX<sub>1</sub> and OX<sub>2</sub> receptor antagonist

Preclinical

  • CT-1500 (CT1500) – adenosine A<sub>1</sub> and A<sub>2A</sub> receptor antagonist

Not under development

No development reported

  • TIK-301 (LY-156735; PD-6735; 6-chloro-β-methylmelatonin) – melatonin MT<sub>1</sub> and MT<sub>2</sub> receptor agonist and serotonin 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptor antagonist

Discontinued

  • BIIB-118 (PF-5251749; PF-05251749) – casein kinase 1 epsilon (CK1ε) and delta (CK1δ) inhibitor
  • LML-134 (LML134) – histamine H<sub>3</sub> receptor antagonist
  • Ramelteon (Rozerem; TAK-375) – melatonin MT<sub>1</sub> and MT<sub>2</sub> receptor agonist

Clinically used drugs

Approved drugs

  • Armodafinil (Nuvigil) – atypical dopamine reuptake inhibitor – specifically for shift work sleep disorder
  • Modafinil (Provigil) – atypical dopamine reuptake inhibitor – specifically for shift work sleep disorder
  • Tasimelteon (BMS-214778; Hetlioz; VEC-162) – melatonin MT<sub>1</sub> and MT<sub>2</sub> receptor agonist

Off-label drugs

See also

References

External links